Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 6/20 | 0.69 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Nitrophenol SCHEMBL31174807 | 0.89 | TGM2 (0.56) | TGM2PPARGPPARAMAPTKLK7 | |
| SCHEMBL13041082 | 0.87 | KLK7 (0.57) | TGM2DPP8DPP9MAPTKLK7 | |
| SCHEMBL18560008 | 0.87 | KLK7 (0.57) | TGM2DPP8DPP9MAPTKLK7 | |
| SCHEMBL2334319 | 0.87 | MAPT (0.68) | TGM2PPARAMAPTKLK7KLK5 | |
| SCHEMBL3210903 | 0.87 | MAPT (0.68) | TGM2PPARAMAPTKLK7KLK5 | |
| SCHEMBL2334326 | 0.87 | MAPT (0.68) | TGM2PPARAMAPTKLK7KLK5 | |
| SCHEMBL29400857 | 0.87 | SIRT5 (0.56) | TGM2MAPTKLK7KLK5SIRT2 | |
| SCHEMBL14334998 | 0.86 | PPARA (0.55) | TGM2PPARGPPARAMAPT | |
| SCHEMBL30684686 | 0.86 | MGLL (0.58) | TGM2PPARGPPARAMAPTITGB3 | |
| SCHEMBL14335086 | 0.85 | PPARA (0.54) | TGM2PPARGPPARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | TGM2 350/4885PPARG 2809/4885PPARA 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.